Tumor-intrinsic metabolic targets, the resulting metabolites, and the drug or compound used against the target that have been evaluated pre-clinically and/or clinically in combination with anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.